KBKristian Bagge

Kristian Bagge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kristian Bagge has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Detectability of Pathogenic RNA Virus Families in Different Body Sites: A Scoping Review

    by Christian Schaadt Ilsby, Thomas Leineweber Kristensen, Kristian Bagge, Jens Bukh, Jan Gorm Lisby, Uffe Vest Schneider

    Nucleic acid amplification tests (NAATs) are central to modern virology diagnostics. However, evidence supporting alternative specimen types remains uneven across viral families, especially for emerging viruses. This limits diagnostic flexibility in outbreak and clinically complex settings. We conducted a scoping review of NAAT detectability across key body sites for human RNA viruses. PubMed and Embase were systematically searched for studies reporting NAAT results from urine, blood, fecal, cerebrospinal fluid, or respiratory specimens. Data were independently screened and synthesized to summarize specimen-specific detectability for each virus. From 8676 screened records, 321 studies were included, covering 39 viruses across 25 RNA virus families. Detectability across specimen types varied substantially between viruses. Consistent detection across multiple specimens was observed for few viruses, including SARS-CoV-2, Zika virus, and HIV, whereas many emerging viruses were evaluated in a single body compartment with limited comparative data. NAAT performance across specimen types is highly virus-specific and unevenly studied, with reliance on blood or respiratory specimens, potentially overlooking viable, less invasive alternatives. Evidence gaps are particularly pronounced for urine and cerebrospinal fluid, and heterogeneous reporting limits cross-study comparability. Standardized, cross-specimen and longitudinal studies are needed to improve diagnostic strategies, outbreak preparedness, and future assay development.

  • Open Access

    The Taxonomy Dictionary: a resource for correct spelling of taxa

    by Kristian Bagge

    This article describes ‘The Taxonomy Dictionary’, a resource that can enhance the spelling engine of a text editor such as Word, so that it can correctly spell every taxon described and listed in the largest taxonomy databases. It contains around 1.4 million unique words, and once installed an incorrectly spelled taxon will be marked by the spelling engine and it will suggest possible correct spellings. Installation instructions for Firefox, LibreOffice and Microsoft Word can be found on the GitHub repository. The software is licensed with a GPL3 licence.

  • Open Access

    The Taxonomy Dictionary. A resource for correct spelling of taxa.

    by Kristian Bagge

    This article describes "The Taxonomy Dictionary". A resource that can enhance the spelling engine of a text editor like Word, so it correctly can spell every taxon described and enlisted in the largest taxonomy databases. It contains around 1.4 million unique words, and once installed a wrongly spelled taxon will be marked by the spelling engine and it will suggest possibly correct spellings. Installation instructions for Firefox, LibreOffice and Microsoft Word can be found on the GitHub repository. The software is licensed with a GPL3 license.

  • Open Access

    The Taxonomy Dictionary. A tool for correct spelling of taxa.

    by Kristian Bagge

    This article describes "The Taxonomy Dictionary". A tool that can enhance the spelling engine of a text editor like Word, so it correctly can spell every taxon described and enlisted in the largest taxonomy databases. It contains 1.412.046 unique words, and once installed a wrongly spelled taxon will be marked by the spelling engine and it will suggest possibly correct spellings. Installation instructions can be found on the GitHub repository. The software is licensed with a GPL3 license.

  • Open Access

    Association between anticoagulant therapy, exacerbations and mortality in a Danish cohort of patients with Chronic Obstructive Pulmonary Disease

    by A Kristensen, P Sivapalan, K Bagge, T Biering-Sørensen, R Sørensen, J Eklöf, Jus Jensen

    Objectives: Pulmonary Embolism has been frequently reported in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD). The study aimed to determine whether COPD patients who receive anticoagulant (AC) therapy have a reduced risk of hospitalization due to AE-COPD and death. Methods: This nationwide population-based study was based on data from the Danish Register of COPD (DrCOPD), which contains complete data on COPD outpatients between 1st January 2010 and 31st December 2018. National registers were used to obtain information regarding comorbidities and vital status. Propensity-score matching and Cox proportional hazards models were used to assess AE-COPD and death after one year. Results: The study cohort consisted of 58,067 patients with COPD. Of these, 5194 patients were on AC therapy. The population was matched 1:1 based on clinical confounders and AC therapy, resulting in two groups of 5180 patients. We found no association between AC therapy and AE-COPD or all-cause mortality in the propensity-score matched population (HR 1.03, 95% CI 0.96-1.10, p = 0.37). These findings were confirmed in a competing risk analysis. In the sensitivity analysis, we performed an adjusted analysis of the complete cohort and found a slightly increased risk of AE-COPD or death in patients treated with AC therapy. This study found a low incidence of pulmonary embolisms and deep venous thrombosis in both groups. Conclusions: AC therapy was not associated with the risk of hospitalization due to AE-COPD or all-cause mortality.


  • Open Access

    Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid—data from 43,636 outpatients

    by Kristian Bagge, Pradeesh Sivapalan, Josefin Eklöf, Frederik Böetius Hertz, Christian Østergaard Andersen, Ejvind Frausing Hansen, Jens Otto Jarløv, Jens-Ulrik Stæhr Jensen

    Background: For antibiotic treatment of Acute exacerbations of COPD (AECOPD) the National guidelines in Denmark recommend either first choice amoxicillin 750 mg TID (AMX) or amoxicillin with clavulanic acid 500 mg/125 mg TID (AMC). Addition of clavulanic acid offers a broader spectrum; opposite, AMX alone in a higher dose may offer more time above MIC. The aim of this study was to determine which of these regimens is associated with better outcome. Methods: The Danish Registry of COPD (DrCOPD), a nationwide outpatient COPD registry, was crosslinked with medication data and hospital contacts. The first prescription of AMX or AMC after inclusion in DrCOPD was used as exposure variable. Adjusted Cox proportional hazards models were used to analyze the risk of hospitalization or death (combined) within 30 days and other endpoints. Results: For the first treatment of AECOPD 12,915 received AMX, and 30,721 patients received AMC. AMX was associated with a decreased risk of pneumonia hospitalization or death (aHR 0.6, 95% CI 0.5–0.7; p < 0.0001) compared to AMC. Conclusion: In AECOPD, empirically adding clavulanic acid to amoxicillin is not associated with a better outcome; it seems safe for these patients to be treated with amoxicillin alone.


  • Open Access

    Streptococcal toxic shock syndrome in a patient with community-acquired pneumonia. Impact of rapid diagnostics on patient management

    by Kristian Bagge, Louise Pedersen, Jan Gorm Lisby

    Here we describe a community-acquired pneumonia with Streptococcus pyogenes , group A following a common cold caused by human metapneumovirus. The patient, a 58-year-old woman with no prior medical history, developed respiratory failure and multi-organ dysfunction caused by streptococcal toxic shock syndrome. The patient was admitted to the intensive care unit and treated with supportive care. The definitive diagnosis was made by BioFire FilmArray by Biomerieux (multiplex PCR) 12 h before positive blood culture, thus enabling the clinician to add clindamycin and intravenous immunoglobulin to the treatment. The patient was discharged fully recovered after 23 days. Streptococci group A is a rare pathogen of severe pneumonia and rapid diagnostics by syndromic testing, potentially performed in a near patient setting, is crucial for early implementation of targeted antimicrobial treatment.


  • Eradicating MRSA carriage: the impact of throat carriage and Panton-Valentine leukocidin genes on success rates

    by Kristian Bagge, Thomas Benfield, Henrik Westh, Mette D. Bartels

    In Denmark, eradication treatment is recommended for methicillin-resistant Staphylococcus aureus (MRSA) carriers. Here, we analyze factors associated with eradication outcome. MRSA carriers referred to the MRSA Knowledge Center at Hvidovre Hospital in 2013 were included. Carriers were sampled from nose, throat, and perineum. Eradication regimen was 5 days of mupirocin nasal ointment and chlorhexidine whole-body wash. Oral antibiotics were sometimes added. Factors associated with eradication after the first eradication attempt were analyzed by logistic regression and expressed as odds ratio (OR) with 95% confidence interval (95% CI). Of 164 individuals, 143 completed 1- and 6-month follow-up after 1st treatment. Eradication was achieved in 63 (38.4%) patients after one treatment and 101 (61.6%) individuals became MRSA free after up to 4 eradication treatments. Throat carriage was associated with a higher failure rate (OR 0.29 (0.10–0.80)), while the presence of Panton-Valentine leukocidin (PVL) genes (37%) was associated with higher success rate (OR 3.52 (1.44–8.57)). Other factors analyzed were not significantly associated with eradication outcome. None of the 26 patients lost to follow-up developed later MRSA infections. This study estimates the efficacy of treatment of MRSA carriage with an eradication rate of 38.4% after the first treatment and a total eradication rate of 61.6% after several treatments. Throat carriers had a lower eradication success rate. Adding oral antibiotics to the first treatment did not increase success. The finding of a significant higher success rate when having a PVL-positive clone should be further investigated.